OTC Watch

All stocks / APTN

ADAPTIN BIO, INC. APTN

Adaptin BIO (APTN): a late 10-K notice in April 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated floatLate filing OTCQBNorth Carolina, USA
Live quote on OTC Markets

Market listing

Full name
ADAPTIN BIO INC.
Market tier
OTCQB
Trading status
Active
Last trade
Sep 07
Website
ir.adaptinbio.com/
Source: Stockwatch, 2026-11-17

News headlines

Adaptin Bio Announces Opening of Enrollment in a Phase 1 Clinical Trial Evaluating Treatment of Malignant Brain Tumors with APTN-101
2026-08-20 16:02 · News Release
Adaptin Bio Shares (Ticker: APTN) Commence Trading on the OTCQB
2026-05-14 13:05 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Net loss
($5,167,569)
What it means

It spends more than it earns

Under strain

The company lost $5.2 million in the year. It reported no sales.

The report says
Cash and cash equivalents
$459,174
Net cash used in operating activities
($4,777,892)
What it means

The cash could run out soon

Under strain

It had $459,174 in the bank and used about $398,158 a month. At that pace the money lasts about 1 months unless it borrows or sells more shares.

The report says
Total assets
$619,159
Total liabilities
$2,108,555
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $619,159. Its debts and unpaid bills add up to $2.1 million. That is about $3.41 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-11-12

Estimated float about 9,261,601 shares as of 2026-11-12: 9,261,601 outstanding minus 0 held by 0 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Late filing2026-04-01

Filed NT 10-K on 2026-04-01: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Shares outstanding

Source: SEC filings
2026-03-26
8.8M
2026-03-31
8.8M
2026-05-14
8.9M
2026-06-11
8.9M
2026-06-30
9.1M
2026-08-11
9.2M
2026-09-30
9.3M
2026-11-12
9.3M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-13 10-QQUARTERLY REPORT
2026-09-10 424B3PROSPECTUS
2026-09-09 EFFECT
2026-08-28 S-1REGISTRATION STATEMENT
2026-08-25 8-KCURRENT REPORT
2026-08-25 424B3PROSPECTUS SUPPLEMENT
2026-08-20 424B3PROSPECTUS SUPPLEMENT
2026-08-13 10-QQUARTERLY REPORT
2026-07-22 EFFECT
2026-07-21 POS AMPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1
2026-06-22 D/A
2026-06-12 10-K/AAMENDMENT NO. 1 TO FORM 10-K

Common questions about APTN

Does APTN file reports with the SEC?

Yes. Adaptin BIO files with the SEC under company number 0001938571. The most recent filing we hold is a 10-Q dated 2026-11-13.

Source record

How many APTN shares are outstanding?

9,261,601 shares as of 2026-11-12, as reported to the SEC.

Source record

Has APTN filed reports late?

Yes. In the last 12 months it filed 1 late-filing notice, most recently a NT 10-K on 2026-04-01. A notice means a report was not ready on time; check whether the report followed.

Source record

Is Adaptin BIO making money?

The company lost $5.2 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record